Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway
Recent studies revealed the relationship among homologous recombination repair (HRR), androgen receptor (AR), and poly(adenosine diphosphate-ribose) polymerase (PARP); however, the synergy between anti-androgen enzalutamide (ENZ) and PARP inhibitor olaparib (OLA) remains unclear. Here, we showed tha...
Main Authors: | Hui-Yu Dong, Pan Zang, Mei-Ling Bao, Tian-Ren Zhou, Chen-Bo Ni, Lei Ding, Xu-Song Zhao, Jie Li, Chao Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=6;spage=687;epage=694;aulast= |
Similar Items
-
Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity
by: María Ovejero-Sánchez, et al.
Published: (2022-07-01) -
Alternative end-joining in BCR gene rearrangements and translocations
by: Bai Wanyu, et al.
Published: (2022-05-01) -
Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01) -
Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01) -
Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
by: Ahmet Dirican, et al.
Published: (2022-11-01)